Lyngstam O, Rydén L
Acta Med Scand. 1981;209(4):261-6.
To compare the antihypertensive effect of two beta-blocking agents, metoprolol (Seloken) and atenolol (Tenormin), a double-blind study was performed in 55 patients. Following a six-week placebo period the patients, who all had mild to moderate essential hypertension (WHO I-II), were randomly allocated to treatment with either metoprolol (n = 28) or atenolol (n = 27). During a six-week period they received 100 mg of either drug once daily. For patients who at the end of that period did not reach a diastolic blood pressure (BP) of less than 95 mmHg the daily dose was increased to 200 mg. Patients who responded (diastolic BP less than 95 mmHg) continued on the initial dosage regimen. When comparing the two groups with regard to the reduction of BP, there was no difference either 24 hours after the last dose or 5-9 hours after drug administration. The decrease in supine systolic/diastolic BP was 18/16 mmHg on metoprolol and 20/16 on atenolol. The decrease in heart rate was comparable in the two groups. Eight patients in the metoprolol and 7 in the atenolol group had their dose increased to 200 mg at the end of the first six-week period. This means that the number of patients not responding to 100 mg daily was comparable in the two groups. We did not observe any differences in side-effects of the two drugs. The results clearly suggest that atenolol and metoprolol are equipotent following once daily administration in patients with mild to moderate hypertension.
为比较两种β受体阻滞剂美托洛尔(倍他乐克)和阿替洛尔(氨酰心安)的降压效果,对55例患者进行了一项双盲研究。在为期六周的安慰剂期后,所有患有轻度至中度原发性高血压(世界卫生组织I-II级)的患者被随机分配接受美托洛尔治疗(n = 28)或阿替洛尔治疗(n = 27)。在六周期间,他们每天服用100毫克这两种药物中的一种。对于在该阶段结束时舒张压未降至95 mmHg以下的患者,每日剂量增加至200毫克。有反应的患者(舒张压低于95 mmHg)继续采用初始剂量方案。在比较两组的血压降低情况时,末次给药后24小时或给药后5 - 9小时均无差异。美托洛尔组仰卧位收缩压/舒张压下降18/16 mmHg,阿替洛尔组下降20/16 mmHg。两组心率下降情况相当。在第一个六周结束时,美托洛尔组有8例患者、阿替洛尔组有7例患者的剂量增加至200毫克。这意味着两组中对每日100毫克剂量无反应的患者数量相当。我们未观察到两种药物在副作用方面存在任何差异。结果清楚地表明,对于轻度至中度高血压患者,每日一次给药后,阿替洛尔和美托洛尔的效力相当。